Sony Biotechnology Inc. Sony Biotechnology Inc.cart
About Us Products What's New Library News Calendar Contact Us Place Order
Safety Data Sheet (SDS) PerCP/Cy55 Anti-mouse IL-10 Antibody     Product Data Sheet (PDF)    
PerCP/Cy5.5 Anti-mouse IL-10 Antibody
3125135 25 µg $120.00       
3125140 100 µg $280.00       
Clone: JES5-16E3
Isotype: Rat IgG2b, κ
Reactivity: Mouse
Immunogen: E. coli-expressed, recombinant mouse IL-10
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.
Concentration: 0.2 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application:

ICFC - Quality tested

Application Notes:

ELISA or ELISPOT Detection1,9,11: The biotinylated JES5-16E3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified JES5-2A5 antibody as the capture antibody.

Neutralization14:

Recommended Usage:

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cy5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Application References:

1. Simkin G, et al. 2000. J. Immunol. 164:2457.
2. Kitagaki K, et al. 2002. Clin. Diagn. Lab Immunol. 9:1260.
3. Khanna A, et al. 2000. J. Immunol. 164:1346.
4. Sander B, et al. 1993. J. Immunol. Methods 166:201.
5. Litton M, et al. 1994. J. Immunol. Methods 175:47.
6. Andersson U, et al. 1999. Detection and qunatification of gene expression. New York:Springer-Verlag.
7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
8. Wang W, et al. 2004. FASEB J. 18:1043.
9. Brummel R and Lenert P. 2005. J. Immunol. 174:2429.
10. Lawson BR, et al. 2007. J. Immunol. 178:5366.
11. Xu G, et al. 2007. J. Immunol. 179:5358. PubMed
12. Brummel R, et al. 2005. J. Immunol.174:2429. PubMed
13. Kang YJ, et al. 2007. Stem Cells 25:1814. PubMed
14. Seo N, et al. 2001. Immunology. 103:449. (Neut)

Th2-polarized lymphocytes from a C57BL/6

Th2-polarized lymphocytes from a C57BL/6 mouse were stimulated with PMA + Ionomycin for 6 hours (in the presence of monensin), surface stained with CD3 APC, fixed, permeabilized, and then stained with IL-10 (clone JES5-16E3) PerCP/Cy5.5 (top) or rat IgG2b PerCP/Cy5.5 isotype control (bottom).





Description:

IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80% sequence homology with the Epstein-Barr virus protein BCRFI. IL-10 inhibits IFN-γ, TNF-β, and IL-2 production by Th1 clones; inhibits macrophage-mediated IL-1, IL-6, and TNF-α synthesis; suppresses the delayed type hypersensitivity response; stimulates Th2 cell response (which results in elevated antibody production); and promotes mast cell proliferation in combination with IL-4.

Other Names: Interleukin-10, Cytokine synthesis inhibitory factor (CSIF), B cell derived T cell growth factor (B-TCGF), T cell growth inhibitory factor (TGIF)
Structure: Acid-labile cytokine, dimer, 17-21 kD (Mammalian)
Regulation: Downregulated by IL-4, IL-10
Cellular Sources: Activated CD8+ T cells, Th0, Th2 subset of CD4+ T cells, Ly-1+ B cells, monocytes, macrophages, keratinocytes
Cellular Targets: T cells, B cells, mast cells, macrophages
Receptors: IL-10R (CDw210)
Antigen References:

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. de Waal-Malefy R, et al. 1992. Curr. Opin. Immunol. 4:314.
3. Howard M, et al. 1992. Immunol. Today 13:198.
4. Quesniaux V. 1992. Res. Immunol. 143:385.
5. Norton SK, et al. 2008. J. Immunol. 180:2848.


This product or portions thereof is manufactured under license from GE Healthcare under U.S. Patent Numbers 5,268,486; 5,569,587; 5,627,027 and patents or pending applications that are continuations, continuations-in-part, re-examinations, divisionals, reissues or foreign equivalents thereof. THIS MATERIAL IS SUBJECT TO PROPRIETARY RIGHTS OF GE HEALTHCARE BIO-SCIENCES CORP. AND CARNEGIE MELLON UNIVERSITY AND MADE AND SOLD UNDER LICENSE FROM GE HEALTHCARE BIO-SCIENCES CORP. THIS PRODUCT IS LICENSED FOR SALE ONLY FOR RESEARCH. IT IS NOT LICENSED FOR ANY OTHER USE. THERE IS NO IMPLIED LICENSE HEREUNDER FOR ANY COMMERCIAL USE.
COMMERCIAL USE shall include:

  • sale, lease, license or other transfer of the material or any material derived or produced from it;
  • sale, lease, license or other grant of rights to use this Material or any material derived or produced from it;
  • use of this material to perform services for a fee for third parties.

IF YOU REQUIRE A COMMERCIAL LICENSE TO USE THIS MATERIAL AND DO NOT HAVE ONE RETURN THIS MATERIAL, UNOPENED TO Sony Biotechnology Inc., 2100 South Oak Street, Champaign, IL 61820, USA AND ANY MONEY PAID FOR THE MATERIAL WILL BE REFUNDED.